Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury

Journal of Molecular and Cellular Cardiology

Volumn 94, Issue , 2016, Pages 82-94

  Carbone, Federico ^a   Crowe, Lindsey A ^b   Roth, Aline ^a   Burger, Fabienne ^a   Lenglet, Sébastien ^a   Braunersreuther, Vincent ^b   Brandt, Karim J ^a   Quercioli, Alessandra ^a   Mach, François ^a   Vallée, Jean Paul ^b   Montecucco, Fabrizio ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Inflammation; Myocardial infarction; Neutrophils

Indexed keywords

CHEMOKINE; CYTOKINE ANTIBODY; GELATINASE B; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; MONOCLONAL ANTIBODY; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; C57BL 6 MOUSE; CELL ISOLATION; CELL MIGRATION; CELL POLARITY; CONTROLLED STUDY; DEGRANULATION; ENZYME RELEASE; GENE IDENTIFICATION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE FUNCTION; MACROPHAGE MIGRATION; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL GRANULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST DIFFERENTIATION FACTOR BLOOD LEVEL; OSTEOCLAST DIFFERENTIATION FACTOR HEART LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPERFUSION INJURY; T LYMPHOCYTE; TISSUE LEVEL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE FUNCTION; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; CELL DEGRANULATION; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; LYMPHOCYTE SUBSETS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL INFILTRATION; NEUTROPHILS; OXIDATIVE STRESS; RANK LIGAND; TROPONIN I; VENTRICULAR DYSFUNCTION;

EID: 84962877691     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.03.013     Document Type: Article

References (37)

1. Kristensen S.D., Laut K.G., Fajadet J., Kaifoszova Z., Kala P., Di Mario C., Wijns W., Clemmensen P., Agladze V., Antoniades L., Alhabib K.F., De Boer M.J., Claeys M.J., Deleanu D., Dudek D., Erglis A., Gilard M., Goktekin O., Guagliumi G., Gudnason T., Hansen K.W., Huber K., James S., Janota T., Jennings S., Kajander O., Kanakakis J., Karamfiloff K.K., Kedev S., Kornowski R., Ludman P.F., Merkely B., Milicic D., Najafov R., Nicolini F.A., Noč M., Ostojic M., Pereira H., Radovanovic D., Sabaté M., Sobhy M., Sokolov M., Studencan M., Terzic I., Wahler S., Widimsky P. European Association for Percutaneous Cardiovascular Interventions, Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur. Heart J. 2014, 35:1957-1970.
2. Carbone F., Nencioni A., Mach F., Vuilleumier N., Montecucco F. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb. Haemost. 2013, 110:501-514.
3. Kain V., Prabhu S.D., Halade G.V. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res. Cardiol. 2014, 109:444.
4. Frantz S., Hofmann U., Fraccarollo D., Schäfer A., Kranepuhl S., Hagedorn I., Nieswandt B., Nahrendorf M., Wagner H., Bayer B., Pachel C., Schön M.P., Kneitz S., Bobinger T., Weidemann F., Ertl G., Bauersachs J. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J. 2013, 27:871-881.
5. Hofmann U., Beyersdorf N., Weirather J., Podolskaya A., Bauersachs J., Ertl G., Kerkau T., Frantz S. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 2012, 125:1652-1663.
6. Y. Ma, A. Yabluchanskiy, R.P. Iyer, P.L. Cannon, E.R. Flynn, M. Jung, J. Henry, C.A. Cates, K.Y. Deleon-Pennell, M.L. Lindsey, Temporal neutrophil polarization following myocardial infarction, Cardiovasc. Res. (2016) doi.org/. doi:10.1093/cvr/cvw024.
7. Braunersreuther V., Montecucco F., Pelli G., Galan K., Proudfoot A.E., Belin A., Vuilleumier N., Burger F., Lenglet S., Caffa I., Soncini D., Nencioni A., Vallée J.P., Mach F. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb. Haemost. 2013, 110:807-825.
8. Liehn E.A., Piccinini A.M., Koenen R.R., Soehnlein O., Adage T., Fatu R., Curaj A., Popescu A., Zernecke A., Kungl A.J., Weber C. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J. Am. Coll. Cardiol. 2010, 56:1847-1857.
9. Montecucco F., Braunersreuther V., Lenglet S., Delattre B.M., Pelli G., Buatois V., Guilhot F., Galan K., Vuilleumier N., Ferlin W., Fischer N., Vallée J.P., Kosco-Vilbois M., Mach F. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur. Heart J. 2012, 33:1964-1974.
10. Cavalera M., Frangogiannis N.G. Targeting the chemokines in cardiac repair. Curr. Pharm. Des. 2014, 20:1971-1979.
11. Lu F., Fernandes S.M., Davis A.E. The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 2013, 22:75-80.
12. Ma X.L., Tsao P.S., Lefer A.M. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J. Clin. Invest. 1991, 88:1237-1243.
13. Williams F.M., Kus M., Tanda K., Williams T.J. Effect of duration of ischaemia on reduction of myocardial infarct size by inhibition of neutrophil accumulation using an anti-CD18 monoclonal antibody. Br. J. Pharmacol. 1994, 111:1123-1128.
14. Quercioli A., Mach F., Bertolotto M., Lenglet S., Vuilleumier N., Galan K., Pagano S., Braunersreuther V., Pelli G., Pistoia V., Bianchi G., Cittadini G., Viviani G.L., Pende A., Roux-Lombard P., Thomas A., Staub C., Ratib O., Dallegri F., Schindler T.H., Montecucco F. Receptor activator of NF-κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb. Haemost. 2012, 107:124-139.
15. Watts N.B., Roux C., Modlin J.F., Brown J.P., Daniels A., Jackson S., Smith S., Zack D.J., Zhou L., Grauer A., Ferrari S. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos. Int. 2012, 23:327-337.
16. Dougall W.C., Holen I., González Suárez E. Targeting RANKL in metastasis. Bonekey Rep. 2014, 3:519.
17. Hageman K., Patel K.C., Mace K., Cooper M.R. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann. Pharmacother. 2013, 47:1069-1074.
18. Montagnana M., Lippi G., Danese E., Guidi G.C. The role of osteoprotegerin in cardiovascular disease. Ann. Med. 2013, 45:254-264.
19. Sakai N., Van Sweringen H.L., Schuster R., Blanchard J., Burns J.M., Tevar A.D., Edwards M.J., Lentsch A.B. Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice. Hepatology 2012, 55:888-897.
20. Shimamura M., Nakagami H., Osako M.K., Kurinami H., Koriyama H., Zhengda P., Tomioka H., Tenma A., Wakayama K., Morishita R. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8191-8196.
21. Montecucco F., Bauer I., Braunersreuther V., Bruzzone S., Akhmedov A., Lüscher T.F., Speer T., Poggi A., Mannino E., Pelli G., Galan K., Bertolotto M., Lenglet S., Garuti A., Montessuit C., Lerch R., Pellieux C., Vuilleumier N., Dallegri F., Mage J., Sebastian C., Mostoslavsky R., Gayet-Ageron A., Patrone F., Mach F., Nencioni A. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid. Redox Signal. 2013, 18:630-641.
22. Baysa A., Sagave J., Carpi A., Zaglia T., Campesan M., Dahl C.P., Bilbija D., Troitskaya M., Gullestad L., Giorgio M., Mongillo M., Di Lisa F., Vaage J.L., Valen G. The p66ShcA adaptor protein regulates healing after myocardial infarction. Basic Res. Cardiol. 2015, 110:13. 10.1007/s00395-015-0470-0.
23. Hughes B.G., Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res. Cardiol. 2014, 109:424.
24. Heusch G. Mitochondria at the heart of cardiovascular protection: p66shc-friend or foe?. Eur. Heart J. 2015, 36:469-471.
25. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 2015, 116:674-699.
26. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., Raffa S., D'anneo G., Lucà F., Mioni C., Arrigo F., Squadrito F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin. Sci. (Lond.) 2005, 109:389-395.
27. Sandberg W.J., Yndestad A., Øie E., Smith C., Ueland T., Ovchinnikova O., Robertson A.K., Müller F., Semb A.G., Scholz H., Andreassen A.K., Gullestad L., Damås J.K., Frøland S.S., Hansson G.K., Halvorsen B., Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 2006, 26:857-863.
28. Benedict P.E., Benedict M.B., Su T.P., Bolling S.F. Opiate drugs and delta-receptor-mediated myocardial protection. Circulation 1999, 100(19 Suppl):II357-II360.
29. Akhmedov A., Montecucco F., Braunersreuther V., Camici G.G., Jakob P., Reiner M.F., Glanzmann M., Burger F., Paneni F., Galan K., Pelli G., Vuilleumier N., Belin A., Vallée J.P., Mach F., Lüscher T.F. Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. Eur. Heart J. 2015, 36. (516-526a).
30. Spescha R.D., Klohs J., Semerano A., Giacalone G., Derungs R.S., Reiner M.F., Rodriguez Gutierrez D., Mendez-Carmona N., Glanzmann M., Savarese G., Kränkel N., Akhmedov A., Keller S., Mocharla P., Kaufmann M.R., Wenger R.H., Vogel J., Kulic L., Nitsch R.M., Beer J.H., Peruzzotti-Jametti L., Sessa M., Lüscher T.F., Camici G.G. Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke. Eur. Heart J. 2015, 36:1590-1600.
31. Copin J.C., da Silva R.F., Fraga-Silva R.A., Capettini L., Quintao S., Lenglet S., Pelli G., Galan K., Burger F., Braunersreuther V., Schaller K., Deruaz M., Proudfoot A.E., Dallegri F., Stergiopulos N., Santos R.A., Gasche Y., Mach F., Montecucco F. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J. Cereb. Blood Flow Metab. 2013, 33:490-498.
32. Montecucco F., Lenglet S., Braunersreuther V., Pelli G., Pellieux C., Montessuit C., Lerch R., Deruaz M., Proudfoot A.E., Mach F. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1371-1377.
33. Musiolik J., van Caster P., Skyschally A., Boengler K., Gres P., Schulz R., Heusch G. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc. Res. 2010, 85:110-117.
34. Nahrendorf M., Sosnovik D., Chen J.W., Panizzi P., Figueiredo J.L., Aikawa E., Libby P., Swirski F.K., Weissleder R. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008, 117:1153-1160.
35. Kohtani T., Abe Y., Sato M., Miyauchi K., Kawachi K. Protective effects of anti-neutrophil antibody against myocardial ischemia/reperfusion injury in rats. Eur. Surg. Res. 2002, 34:313-320.
36. M. Horckmans, L. Ring, J. Duchene, D. Santovito, M.J. Schloss, M. Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur. Heart J. (2016) doi.org/. doi:10.1093/eurheartj/ehw002.
37. Yan X., Anzai A., Katsumata Y., Matsuhashi T., Ito K., Endo J., Yamamoto T., Takeshima A., Shinmura K., Shen W., Fukuda K., Sano M. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J. Mol. Cell. Cardiol. 2013, 62:24-35.